# Retatrutide TRIUMPH-1 Phase 3 Results: How to Track the 28.3% Weight Loss Data
Retatrutide just got its clearest obesity trial signal yet.
On May 21, 2026, Eli Lilly announced topline results from TRIUMPH-1, a Phase 3 trial evaluating retatrutide in adults with obesity or overweight, at least one weight-related comorbidity, and no diabetes. Retatrutide is still investigational and is not FDA-approved, but this readout matters because it gives the peptide community a more specific map of dose, response, tolerability, and what still needs to be watched.
The headline number is obvious: participants on 12 mg retatrutide lost an average of 70.3 pounds, or 28.3% of body weight, over 80 weeks. In a prespecified extension for participants who started with BMI 35 or higher, those continuing to 104 weeks lost up to 85.0 pounds, or 30.3%, on average.
But the more useful takeaway is not just "bigger number." It is that TRIUMPH-1 gives three separate dose lanes: 4 mg, 9 mg, and 12 mg. For anyone trying to understand where retatrutide may fit relative to other GLP-1-based therapies, the lower-dose data may be just as important as the top-dose headline.
What TRIUMPH-1 Actually Studied
TRIUMPH-1 was an 80-week, randomized, double-blind, placebo-controlled Phase 3 master trial. The trial randomized 2,339 participants in a 1:1:1:1 ratio to retatrutide 4 mg, retatrutide 9 mg, retatrutide 12 mg, or placebo.
All retatrutide groups started at 2 mg once weekly and escalated stepwise every four weeks until they reached the assigned target dose. The 4 mg group had one escalation step. The 9 mg and 12 mg groups had more escalation steps, which matters because tolerability often changes during titration.
Lilly also included basket-trial components for knee osteoarthritis pain and moderate-to-severe obstructive sleep apnea, but the topline release focused on the obesity master trial and the BMI 35-plus extension period. The additional basket-trial analyses are expected separately.
The Dose-Response Data
At 80 weeks, the efficacy-estimand results were:
- 4 mg retatrutide: 47.2 pounds lost, or 19.0% body weight reduction
- 9 mg retatrutide: 64.4 pounds lost, or 25.9% body weight reduction
- 12 mg retatrutide: 70.3 pounds lost, or 28.3% body weight reduction
- Placebo: 5.5 pounds lost, or 2.2% body weight reduction
- 4 mg: 4.1%
- 9 mg: 6.9%
- 12 mg: 11.3%
- Placebo: 4.9%
The 12 mg result is the one most people will quote. It is a large effect, especially because 45.3% of participants in that arm achieved 30% or more body weight reduction at 80 weeks.
But the 4 mg arm is the quiet signal. A 19.0% average reduction with a simpler escalation path suggests retatrutide may eventually be discussed as more than a maximum-dose-only molecule. If future data supports it, clinicians may have a meaningful range of dose options instead of treating the top dose as the only interesting endpoint.
Why the Mechanism Matters
Retatrutide is a triple hormone receptor agonist. It activates receptors for GLP-1, GIP, and glucagon. GLP-1 supports satiety and glucose control. GIP may add incretin and metabolic signaling alongside GLP-1. Glucagon is the differentiating pathway and may contribute to higher energy expenditure and fat oxidation.
This does not make retatrutide a magic peptide. It means the trial is testing a broader receptor profile than semaglutide or tirzepatide. That broader profile may explain why the weight-loss ceiling appears higher, but it also makes careful tracking more important. More pathways can mean more variables to monitor.
The Tolerability Tradeoff
The most common adverse events in TRIUMPH-1 were familiar for incretin-based therapies: nausea, diarrhea, constipation, vomiting, and upper respiratory tract infection. Lilly also reported dysesthesia more often in retatrutide groups than placebo.
Discontinuation rates due to adverse events were dose-dependent:
That pattern is exactly why the dose-response data matters. The 12 mg arm delivered the largest average loss, but also had the highest adverse-event discontinuation rate. The 4 mg arm delivered a large average loss with a discontinuation rate lower than placebo in the topline release. That does not mean 4 mg is "better" for everyone. It means the best future protocol may be the dose that produces enough response with tolerable side effects, not simply the highest available dose.
What PeptIQ Users Should Track
If you are following retatrutide research or tracking an investigational protocol under appropriate medical oversight, TRIUMPH-1 points to a better tracking framework.
Dose and titration step. Do not only log the weekly dose. Log the titration stage. A side effect on week two of a dose increase is different from a side effect after eight stable weeks.
Weight trend, not daily noise. The trial measured long-term change over 80 weeks. Daily scale weight is too noisy to interpret alone. Track weekly averages, waist circumference, appetite, and strength markers.
GI side effects by severity. Record nausea, diarrhea, constipation, vomiting, reflux, and appetite suppression separately. A single "felt bad" note is hard to act on later.
Sensory changes. Because dysesthesia appeared more often in retatrutide-treated groups, unusual tingling, burning, skin sensitivity, or altered sensation should be logged clearly with date, dose, duration, and whether it resolved.
Protein, training, and lean mass signals. Large weight loss is not automatically high-quality weight loss. Track protein intake, resistance training, strength performance, body measurements, and any available body-composition data.
What This Does Not Mean Yet
Retatrutide is not FDA-approved. Lilly states that it is legally available only to participants in Lilly clinical trials. The topline release is also not the same thing as a full peer-reviewed paper, and more detailed results are expected at medical meetings and in future publications.
That distinction matters. The responsible interpretation is: TRIUMPH-1 strengthens the clinical case for retatrutide, but it does not validate black-market products, copycat protocols, or unlabeled research-vendor dosing.
Frequently Asked Questions
Q: Is retatrutide approved now?
A: No. Retatrutide remains investigational and is not approved by the FDA or any regulatory agency.
Q: What was the highest weight-loss result in TRIUMPH-1?
A: In the 80-week efficacy-estimand analysis, the 12 mg group lost an average of 70.3 pounds, or 28.3% of body weight. In the BMI 35-plus extension, participants continuing to 104 weeks lost up to 85.0 pounds, or 30.3%, on average.
Q: Is 12 mg the only dose that matters?
A: No. The 4 mg group lost 19.0% on average at 80 weeks, while the 9 mg group lost 25.9%. The lower-dose data may become important for people who need a better tolerability balance.
Q: What side effects should people watch most closely?
A: The topline release emphasized nausea, diarrhea, constipation, vomiting, upper respiratory tract infection, dysesthesia, and urinary tract infections. Any persistent or severe symptoms should be discussed with a qualified clinician.
Q: How should I compare this to tirzepatide or semaglutide?
A: Compare mechanism, dose, trial population, duration, discontinuation rates, and body-composition outcomes. Do not compare headline weight-loss percentages without checking those details.
Track the Protocol, Not Just the Scale
The TRIUMPH-1 results are strong, but the practical lesson is disciplined tracking. Dose, titration, side effects, appetite, waist, training, protein, and notes all matter.
PeptIQ is built for that level of clarity: log your protocol, track response over time, and keep the signal separate from the noise.
Download PeptIQ - Premium; annual includes a 3-day trial.
